Immuneering Corporation (IMRX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors' data.
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
Immuneering Corporation: Updates Inbound At The End Of The Month
Immuneering Corporation (IMRX) presents promising early data in frontline metastatic pancreatic cancer with its MEK inhibitor atebimetinib, benchmarking favorably against Revolution Medicines. IMRX's 12-month overall survival rate of 64% in a small phase 2a trial compares well to historical controls and competitive agents, but caution is warranted due to trial size. The company maintains over $200 million in liquidity, supporting a cash runway into 2029, though future trial costs may shorten this horizon.
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts.
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data
Immuneering Corporation remains a Strong Buy after 12-month OS data for atebimetinib + mGnP in 1st-line pancreatic cancer showed a robust 64% rate. IMRX's combination nearly doubles standard-of-care 12-month OS (64% vs. 35%), with a favorable safety profile and regulatory alignment for phase 3 initiation mid-2026. Market overreacted to the OS decline from 9 to 12 months; cross-trial comparisons are misleading and do not reflect the differentiated mechanism of IMRX's MEK inhibitor.
Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript
Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy
Immuneering (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock?
Immuneering (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High?
The mean of analysts' price targets for Immuneering (IMRX) points to a 126.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript
Immuneering Corporation ( IMRX ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Benjamin Zeskind - Co-Founder, President, CEO & Director Mallory Morales - Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer Conference Call Participants Laurence Watts - Gilmartin Group LLC Allyson Ocean Gregory Botta Jay Olson - Oppenheimer & Co. Inc., Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Ami Fadia - Needham & Company, LLC, Research Division Presentation Operator Welcome to the Immuneering Conference Call to discuss the Company's Third Quarter 2025 Financial Results and share investigator-presented clinical case studies in pancreatic patients. [Operator Instructions] I would now like to turn the call conference over to Laurence Watts of New Street Investor Relations.
Immuneering Stock Rises 21.7% on Supply Agreement With LLY
IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.
